VYR-2020

VYR-2020 is an investigational **antiviral diagnostic agent** being developed by Vyripharm for viral infections including COVID-19. Publicly available information indicates it is part of Vyripharm's nuclear medicine and theranostic platform and is intended for **in vivo diagnostic imaging and evaluation of treatment response**, rather than as a conventional approved therapeutic drug. The exact chemical identity, radionuclide, formulation, administration route, and molecular target have not been clearly disclosed in reliable public primary sources, but company materials describe VYR-2020 as an antiviral program redirected toward COVID-19 and other viral infections such as SARS and MERS, with preclinical manufacturing support from Regis Technologies and no clear evidence of clinical-stage advancement.